Accessibility Menu
Bavarian Nordic A/s logo

Bavarian Nordic A/s(OTC) BVNKF

Current Price$27.69
Market Cap$2.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-20%
5 Year-40%
1 Year+4%
1 Month-0%
Bavarian Nordic A/s last closing stock price
MetricPriceDate
Last closeUSD 27.692026-07-20
Bavarian Nordic A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 27.692026-07-09
1 month-0.39%USD 27.802026-06-18
3 month-9.88%USD 30.732026-04-20
Year to date-6.13%USD 29.502025-12-31
1 year+4.46%USD 26.512025-07-18
3 year+2.04%USD 27.142023-07-20
5 year-39.8%USD 46.002021-06-18
Since inception-20.08%USD 34.652003-11-14

Bavarian Nordic A/s Financials at a Glance

Market Cap

$2.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 5.92B

Net Income (TTM)

DKK 1.17B

EPS (TTM)

$2.33

P/E Ratio

11.87

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$27.69

Volume

73

Open

$27.69

Previous Close

$27.69

Daily Range

$27.69 - $27.69

52-Week Range

$27.69 - $37.61

Estimated Earnings Date

Aug 21, 2026

BVNKF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bavarian Nordic A/s

Bavarian Nordic A/S is a biotechnology company focused on developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. Headquartered in Hellerup, Denmark, the company specializes in therapeutic vaccines targeting various cancers, including breast, lung, ovarian, and prostate cancer.

Products and Services
  • Innovative cancer immunotherapies targeting multiple cancer types
  • Vaccines for infectious diseases, enhancing public health
  • Robust pipeline of therapeutic vaccines in development
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Increasing demand for cancer immunotherapy solutions
  • Strategic partnerships enhancing market reach and capabilities
Financial Highlights
  • Recent quarterly revenue of 1.06 billion DKK, showing growth potential
  • TTM net profit margin of 19.83%, indicating operational efficiency
  • Current ratio of 6.47, reflecting strong liquidity position
Bavarian Nordic A/S is positioned in a growing sector with a focus on innovative solutions for cancer treatment and infectious diseases. The company's strong financial metrics, including a solid net profit margin and high liquidity, suggest a stable operational foundation. With a promising pipeline and strategic partnerships, Bavarian Nordic is well-placed to capitalize on the increasing demand for advanced therapeutic options in the healthcare market.
AI Generated • Jul 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,861

CEO

Paul Chaplin, PhD

Website

www.bavarian-nordic.com

Headquarters

Hellerup, CR 2900, DK

BVNKF Financials

Key Financial Metrics (TTM)

Gross Margin

47.40%

Operating Margin

25.36%

Net Income Margin

19.83%

Return on Equity

9.25%

Return on Capital

7.08%

Return on Assets

8.32%

Earnings Yield

8.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.14M

Volume

73

Avg. Volume

115.532

Financials (TTM)

Gross Profit

DKK 2.80B

Operating Income

DKK 1.50B

EBITDA

DKK 2.25B

Operating Cash Flow

DKK 2.36B

Capital Expenditure

-DKK 981.23M

Free Cash Flow

DKK 1.37B

Cash & ST Invst.

DKK 2.29B

Total Debt

DKK 139.43M

Bavarian Nordic A/s Performance Analysis

Bavarian Nordic A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 445,115,54548.1%
20232023-12-31DKK 1,023,994,200130.1%
20242024-12-31DKK 828,183,526-19.1%
20252025-12-31DKK 933,164,96812.7%
Bavarian Nordic A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.6%
Q32025-09-308.7%
Q42025-12-31-21.4%
Q12026-03-31-24.8%
Bavarian Nordic A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK -0.70-40.5%
20232023-12-31DKK 2.79N/A
20242024-12-31DKK 1.83-34.3%
20252025-12-31DKK 2.6745.3%
Bavarian Nordic A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3066.7%
Q32025-09-30204.4%
Q42025-12-31-127.9%
Q12026-03-31105.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

DKK 1.06B

-21.3%

Gross Profit

DKK 475.49M

-30.1%

Gross Margin

44.87%

N/A

Market Cap

$2.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.22M

N/A

Employees

1,744

N/A

Net Income

DKK 16.97M

-92.2%

EBITDA

DKK 166.42M

-58.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

DKK 2.29B

+85.7%

Total Debt

DKK 139.43M

+19.2%

Accounts Receivable

DKK 937.38M

-20.1%

Inventory

DKK 2.67B

+7.9%

Long Term Debt

DKK 93.56M

+21.6%

Short Term Debt

DKK 45.82M

+14.6%

Return on Assets

8.32%

N/A

Return on Invested Capital

11.39%

N/A

Free Cash Flow

-DKK 784.73M

-4.0%

Operating Cash Flow

-DKK 752.57M

-94.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GLPGFGalapagos N.V.
$28.08+0.00%
HYPMYHypera S.A.
$3.98-0.25%
BRCTFBioArctic AB (publ)
$31.78+0.00%
TLPPFTelix Pharmaceuticals Limited
$10.48+0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About BVNKF

What is the current price of Bavarian Nordic A/s?

Bavarian Nordic A/s is trading at $27.69 per share.

What is the 52-week range for Bavarian Nordic A/s?

Over the past 52 weeks, Bavarian Nordic A/s has traded between $27.69 and $37.61.

How much debt does Bavarian Nordic A/s have?

As of the most recent reporting period, Bavarian Nordic A/s reported total debt of DKK 21.48M.

How much cash does Bavarian Nordic A/s have on hand?

Bavarian Nordic A/s reported DKK 106.83M in cash and cash equivalents in its most recent financial results.

What is Bavarian Nordic A/s’s dividend yield?

Bavarian Nordic A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services